Treatment with ABT-199 efficiently and selectively disrupted BCL-2–BIM complexes in MDS-L cells without affecting BCL-XL–BIM and MCL-1–BIM complexes, confirming target engagement by ABT-199 in the xenografts (Extended Data Fig. 9f). This evidence concerns the gene BCL2L1 and myelodysplastic syndrome.